Investigating psychotropic properties of antiepileptic drugs

References

• Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53(Suppl. 7), 26–33 (2012).
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1), 27–47 (2008).
   PubMed Web of Science ®Google Scholar
• Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 30(7), 555–567 (2007).
   PubMed Web of Science ®Google Scholar
• Chris Sackellares J, Jacqueline Kwong W, Vuong A, Hammer AE, Barrett PS. Lamotrigine monotherapy improves health-related quality of life in epilepsy: a double-blind comparison with valproate. Epilepsy Behav. 3(4), 376–382 (2002).
   PubMedGoogle Scholar
• Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 380(9848), 1180–1192 (2012).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol. Disord. Drug Targets 6(2), 127–140 (2007).
   PubMedGoogle Scholar
• Comai S, Tau M, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J. Clin. Psychopharmacol. 32(1), 83–94 (2012).
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord. 11(1), 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Mula M. New antiepileptic drugs: molecular targets. Cent. Nerv. Syst. Agents Med. Chem. 9(2), 79–86 (2009).
   PubMedGoogle Scholar
• Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5(7), 553–564 (2004).
   PubMed Web of Science ®Google Scholar
• Mula M. GABAergic drugs in the treatment of epilepsy: modern or outmoded? Future Med. Chem. 3(2), 177–182 (2011).
   PubMedGoogle Scholar
• Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 6(3), 215–229 (2005).
   PubMed Web of Science ®Google Scholar
• Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav. Brain Funct. 8, 61 (2012).
   PubMed Web of Science ®Google Scholar
• Marx CE, Stevens RD, Shampine LJ et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 31(6), 1249–1263 (2006).
   PubMed Web of Science ®Google Scholar
• Pieribone VA, Tsai J, Soufflet C et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia 48(10), 1870–1874 (2007).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92(2–3), 89–124 (2010).
   PubMed Web of Science ®Google Scholar
• Hu AQ, Wang ZM, Lan DM et al. Inhibition of evoked glutamate release by neurosteroid allopregnanolone via inhibition of l-type calcium channels in rat medial prefrontal cortex. Neuropsychopharmacology 32(7), 1477–1489 (2007).
   PubMedGoogle Scholar
• Mula M. Recent and future antiepileptic drugs and their impact on cognition: what can we expect? Expert Rev. Neurother. 12(6), 667–671 (2012).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 103(1), 2–30 (2013).
   PubMed Web of Science ®Google Scholar
• No authors listed. Gamma-aminobutyric acid (GABA), monograph. Altern. Med. Rev. 12(3), 274–279 (2007).
   PubMedGoogle Scholar
• Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 150(11), 1731–1733 (1993).
   PubMed Web of Science ®Google Scholar
• Mauri MC, Ferrara A, Boscati L et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37(3), 124–129 (1998).
   PubMed Web of Science ®Google Scholar
• Sheline YI. Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity? Mol. Psychiatry 1(4), 298–299 (1996).
   PubMed Web of Science ®Google Scholar
• Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 57(10), 925–935 (2000).
   PubMed Web of Science ®Google Scholar
• Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets 9(1), 153–168 (2005).
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 4(1), 18–61 (2007).
   PubMed Web of Science ®Google Scholar
• Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 49(5), 888–897 (2008).
   PubMed Web of Science ®Google Scholar
• Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl. 1), S10–S16 (2000).
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Lamotrigine – a novel approach. Seizure 3(Suppl. A), 41–45 (1994).
   PubMedGoogle Scholar
• Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39(11), 2139–2146 (2000).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 12(10), 2255–2258 (2001).
   PubMed Web of Science ®Google Scholar
• Gay PE, Mecham GF, Coskey JS, Sadler T, Thompson JA. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). Psychol. Rep. 77(3 Pt 2), 1208–1210 (1995).
   PubMedGoogle Scholar
• Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53(5 Suppl. 2), S53–S67 (1999).
   PubMed Web of Science ®Google Scholar
• Frye MA. Clinical practice. Bipolar disorder – a focus on depression. N. Engl. J. Med. 364(1), 51–59 (2011).
   PubMed Web of Science ®Google Scholar
• Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int. Clin. Psychopharmacol. 22(3), 179–182 (2007).
   PubMed Web of Science ®Google Scholar
• Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 10(1), 148–154 (2007).
   PubMed Web of Science ®Google Scholar
• Tritt K, Nickel C, Lahmann C et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J. Psychopharmacol. (Oxford) 19(3), 287–291 (2005).
   PubMed Web of Science ®Google Scholar
• Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int. Clin. Psychopharmacol. 24(5), 270–275 (2009).
   PubMed Web of Science ®Google Scholar
• Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav. 26(3), 440–449 (2013).
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44(5), 659–663 (2003).
   PubMed Web of Science ®Google Scholar
• Nickel C, Lahmann C, Tritt K et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J. Affect. Disord. 87(2–3), 243–252 (2005).
   PubMed Web of Science ®Google Scholar
• Nickel MK, Nickel C, Mitterlehner FO et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J. Clin. Psychiatry 65(11), 1515–1519 (2004).
   PubMed Web of Science ®Google Scholar
• Nickel MK, Nickel C, Kaplan P et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol. Psychiatry 57(5), 495–499 (2005).
   PubMed Web of Science ®Google Scholar
• Leombruni P, Lavagnino L, Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr. Dis. Treat. 5, 385–392 (2009).
   PubMed Web of Science ®Google Scholar
• Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol. 27(3), 263–272 (2007).
   PubMed Web of Science ®Google Scholar
• Delbello MP, Findling RL, Kushner S et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 44(6), 539–547 (2005).
   PubMed Web of Science ®Google Scholar
• Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR; Clinical Affairs Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J. Clin. Psychiatry 67(11), 1698–1706 (2006).
   PubMed Web of Science ®Google Scholar
• Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J. Clin. Psychopharmacol. 27(6), 677–681 (2007).
   PubMed Web of Science ®Google Scholar
• Tucker P, Trautman RP, Wyatt DB et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(2), 201–206 (2007).
   PubMed Web of Science ®Google Scholar
• Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr. Dis. Treat. 2(4), 475–488 (2006).
   PubMedGoogle Scholar
• French JA, Krauss GL, Biton V et al. Adjunctive perampanel for refractory partial-onset seizures: randomized Phase III study 304. Neurology 79(6), 589–596 (2012).
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V et al. Randomized Phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78(18), 1408–1415 (2012).
   PubMed Web of Science ®Google Scholar
• Rektor I, Krauss GL, Bar M et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol. Scand. 126(4), 263–269 (2012).
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from Phase III, extension study 307. Epilepsia 54(1), 126–134 (2013).
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 54(1), 117–125 (2013).
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Huff MO. Mood stabilizers and ion regulation. Harv. Rev. Psychiatry 9(1), 23–32 (2001).
   PubMed Web of Science ®Google Scholar
• Mogilnicka E, Czyrak A, Maj J. Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action. Eur. J. Pharmacol. 138(3), 413–416 (1987).
   PubMed Web of Science ®Google Scholar
• Galeotti N, Bartolini A, Ghelardini C. Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test. Neuropharmacology 50(3), 309–316 (2006).
   PubMed Web of Science ®Google Scholar
• Quintero JE, Dooley DJ, Pomerleau F, Huettl P, Gerhardt GA. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ a2d-1 subunit. J. Pharmacol. Exp. Ther. 338(1), 240–245 (2011).
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett. 280(2), 107–110 (2000).
   PubMed Web of Science ®Google Scholar
• Farber NB, Jiang XP, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol. Psychiatry 7(7), 726–733 (2002).
   PubMed Web of Science ®Google Scholar
• Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378(9799), 1306–1315 (2011).
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco F. Phenytoin and other hydantoins: clinical efficacy and use in psychiatric disorders. In: Antiepileptic Drugs (5th Edition). Levy R, Mattson R, Meldrum B, Perucca E (Eds). Lippincott William & Wilkins, Baltimore, MD, USA, 600–604 (2002).
   Google Scholar
• Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci. Ther. 17(3), 167–177 (2011).
   PubMed Web of Science ®Google Scholar
• Fornaro M, Martino M, Dalmasso B et al. An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects. Ann. Gen. Psychiatry 10(1), 23 (2011).
   PubMedGoogle Scholar
• Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacol. Bull. 44(1), 5–17 (2011).
   PubMedGoogle Scholar
• Stahl SM. Mechanism of action of α2δ ligands: voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry 65(8), 1033–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Micó JA, Prieto R. Elucidating the mechanism of action of pregabalin: a(2)d as a therapeutic target in anxiety. CNS Drugs 26(8), 637–648 (2012).
   PubMed Web of Science ®Google Scholar
• Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry 193(5), 389–394 (2008).
   PubMed Web of Science ®Google Scholar
• Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 24(2), 87–96 (2009).
   PubMed Web of Science ®Google Scholar
• Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int. Clin. Psychopharmacol. 26(4), 213–220 (2011).
   PubMed Web of Science ®Google Scholar
• Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int. Clin. Psychopharmacol. 26(5), 243–251 (2011).
   PubMed Web of Science ®Google Scholar
• Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M. Augmentation with pregabalin in schizophrenia. J. Clin. Psychopharmacol. 30(4), 437–440 (2010).
   PubMed Web of Science ®Google Scholar
• Showraki M. Pregabalin in the treatment of depression. J. Psychopharmacol. (Oxford) 21(8), 883–884 (2007).
   PubMed Web of Science ®Google Scholar
• Vieta E, Manuel Goikolea J, Martínez-Arán A et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J. Clin. Psychiatry 67(3), 473–477 (2006).
   PubMed Web of Science ®Google Scholar
• Schifano F, D’Offizi S, Piccione M et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother. Psychosom. 80(2), 118–122 (2011).
   PubMed Web of Science ®Google Scholar
• Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. 23(9), 393–398 (2000).
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Hirai H, Iino M et al. Inhibitory effects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels. Neuropharmacology 56(2), 499–506 (2009).
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther. 295(3), 1086–1093 (2000).
   PubMed Web of Science ®Google Scholar
• Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res. 63(1), 17–25 (2005).
   PubMed Web of Science ®Google Scholar
• Madeja M, Margineanu DG, Gorji A et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 45(5), 661–671 (2003).
   PubMed Web of Science ®Google Scholar
• Deeks ED. Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. CNS Drugs 25(10), 887–900 (2011).
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 15(5), 339–350 (2001).
   PubMed Web of Science ®Google Scholar
• Barrese V, Miceli F, Soldovieri MV et al. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clin. Pharmacol. 2, 225–236 (2010).
   PubMedGoogle Scholar
• Dencker D, Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav. Brain Res. 207(1), 78–83 (2010).
   PubMedGoogle Scholar
• Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strøbaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J. Pharmacol. Exp. Ther. 314(1), 282–292 (2005).
   PubMedGoogle Scholar
• Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68(15), 1197–1204 (2007).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A et al.; RESTORE 2 Study Group. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75(20), 1817–1824 (2010).
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF et al.; RESTORE 1/Study 301 Investigators. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76(18), 1555–1563 (2011).
   PubMed Web of Science ®Google Scholar
• Potiga. Precribing information. GlaxoSmithKline, Research Triangle Park, NC, USA, 29 June 2012.
   Google Scholar
• Hilfiker S, Pieribone VA, Czernik AJ, Kao HT, Augustine GJ, Greengard P. Synapsins as regulators of neurotransmitter release. Philos. Trans. R. Soc. Lond. B, Biol. Sci. 354(1381), 269–279 (1999).
   PubMedGoogle Scholar
• Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 26(4), 1303–1313 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101(26), 9861–9866 (2004).
   PubMed Web of Science ®Google Scholar
• Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs 20(12), 969–979 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J. Psychopharmacol. (Oxford) 19(5), 551–553 (2005).
   PubMed Web of Science ®Google Scholar
• Saricicek A, Maloney K, Muralidharan A et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 72(6), 744–750 (2011).
   PubMed Web of Science ®Google Scholar
• Stein MB, Ravindran LN, Simon NM et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J. Clin. Psychiatry 71(5), 627–631 (2010).
   PubMed Web of Science ®Google Scholar
• Mattes JA. Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 69(2), 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 61(5), 704–706 (2003).
   PubMed Web of Science ®Google Scholar
• White JR, Walczak TS, Leppik IE et al. Discontinuation of levetiracetam because of behavioral side effects: a case–control study. Neurology 61(9), 1218–1221 (2003).
   PubMed Web of Science ®Google Scholar
• Helmstaedter C, Mihov Y, Toliat MR et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia 54(1), 36–44 (2013).
   PubMed Web of Science ®Google Scholar
• Post RM, Silberstein SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology 44(10 Suppl. 7), S37–S47 (1994).
   PubMedGoogle Scholar
• Kanner AM. Depression and epilepsy: a bidirectional relation? Epilepsia 52(Suppl. 1), 21–27 (2011).
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(2), 209–224 (2004).
   PubMedGoogle Scholar
• Amann B, Grunze H. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia 46(Suppl. 4), 26–30 (2005).
   PubMed Web of Science ®Google Scholar
• Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML. Effects of medication on neuroimaging findings in bipolar disorder: an updated review. Bipolar Disord. 14(4), 375–410 (2012).
   PubMed Web of Science ®Google Scholar
• Post RM, Weiss SR. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol. Neurobiol. 13(1), 33–60 (1996).
   PubMed Web of Science ®Google Scholar
• Potschka H, Feuerstein TJ, Löscher W. Gabapentin-lactam, a close analogue of the anticonvulsant gabapentin, exerts convulsant activity in amygdala kindled rats. Naunyn Schmiedebergs Arch. Pharmacol. 361(2), 200–205 (2000).
   PubMedGoogle Scholar
• Mula M. Topiramate and cognitive impairment: evidence and clinical implications. Ther. Adv. Drug Saf. 3(6), 279–289 (2012).
   PubMedGoogle Scholar
• Bersudsky Y, Applebaum J, Gaiduk Y et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord. 12(4), 376–382 (2010).
   PubMed Web of Science ®Google Scholar
• Zullino DF, Khazaal Y, Hättenschwiler J, Borgeat F, Besson J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today 40(7), 603–619 (2004).
   PubMed Web of Science ®Google Scholar
• Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst. Rev. 3, CD005194 (2006).
   PubMedGoogle Scholar